跳到正文
原文
Nature Medicine· Georgina V. Long·· 2026-10-01精选AI 评分78

黑色素瘤新辅助治疗后五年生存:INMC更新合并分析

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

AI 导读

国际新辅助黑色素瘤协作组(INMC)更新了一项合并分析,纳入1,038名接受新辅助免疫检查点抑制剂(ICI)、BRAF/MEK抑制剂或联合治疗的黑色素瘤患者。结果显示,ICI单药或联合治疗在3年及5年生存等指标上优于BRAF/MEK抑制剂,且达到主要病理缓解的患者长期生存更好。

推荐理由

原文明确指出主要病理缓解与长期生存相关,读者可据此理解该观察性研究的局限与临床含义。

正文

Nature Medicine, Published online: 01 October 2026; doi:10.1038/s41591-026-04677-z

An updated pooled analysis of 3-year and 5-year survival and other outcome data of 1,038 patients with melanoma treated with neoadjuvant immune checkpoint inhibitors (ICIs), BRAF and MEK inhibitors (BRAF/MEKis), or a combination of ICIs and targeted therapies shows that ICI as monotherapy or in ICI combinations are superior to BRAF/MEKis and patients with major pathological responses have better long-term survival.

来源:Nature Medicine · nature.com